Show simple item record

dc.contributor.authorKingston, B
dc.contributor.authorKayhanian, H
dc.contributor.authorBrooks, C
dc.contributor.authorCox, N
dc.contributor.authorChaabouni, N
dc.contributor.authorRedana, S
dc.contributor.authorKalaitzaki, E
dc.contributor.authorSmith, I
dc.contributor.authorO'Brien, M
dc.contributor.authorJohnston, S
dc.contributor.authorParton, M
dc.contributor.authorNoble, J
dc.contributor.authorStanway, S
dc.contributor.authorRing, A
dc.contributor.authorTurner, N
dc.contributor.authorOkines, A
dc.date.accessioned2017-11-23T10:18:23Z
dc.date.issued2017-12-01
dc.identifier.citationBreast (Edinburgh, Scotland), 2017, 36 pp. 54 - 59
dc.identifier.issn0960-9776
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/937
dc.identifier.eissn1532-3080
dc.identifier.doi10.1016/j.breast.2017.07.015
dc.description.abstractPURPOSE: Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The prognosis is poor, and although radiotherapy (RT), systemic and intra-thecal (IT) chemotherapy are accepted treatment modalities, efficacy data are limited. This study was designed to evaluate potential predictors of survival in this patient group. METHODS: Breast cancer patients with LMD diagnosed by MRI in a 10-year period (2004-2014) were identified from electronic patient records. PFS and OS estimates were calculated using Kaplan-Meier method, with planned sub-group analysis by treatment modality. Cox regression was employed to identify significant prognostic variables. RESULTS: We identified 182 eligible patients; all female, median age at LMD diagnosis 52.5 years (range 23-80). Ninety patients (49.5%) were ER positive/HER2 negative; 48 (26.4%) were HER2 positive, and 27 (14.8%) were triple negative. HER2 status was unknown in 17 (9.3%). Initial management of LMD was most commonly whole or partial brain RT in 62 (34.1%), systemic therapy in 45 (24.7%) or supportive care alone in 37 (20.3%). Fourteen patients (7.7%) underwent IT chemotherapy, of whom two also received IT trastuzumab. From diagnosis of LMD, the median PFS was 3.9 months (95%CI 3.2-5.0) and median OS was 5.4 months (95%CI 4.2-6.6). Patients treated with systemic therapy had the longest OS (median 8.8 months, 95%CI 5.5-11.1), compared to RT; 6.1 months (95%CI 4.2-7.9 months), IT therapy; 2.9 months (95%CI 1.2-5.8) and supportive care; 1.7 months (95%CI 0.9-3.0). On multivariable analysis, triple negative histology, concomitant brain metastases, and LMD involving both the brain and spinal cord were associated with poor OS. CONCLUSIONS: Breast cancer patients with triple negative LMD, concomitant brain metastases or LMD affecting both the spine and brain have the poorest prognosis. Clinical trials to identify more effective treatments for these patients are urgently needed.
dc.formatPrint-Electronic
dc.format.extent54 - 59
dc.languageeng
dc.language.isoeng
dc.publisherCHURCHILL LIVINGSTONE
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectBrain
dc.subjectSpinal Cord
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectBrain Neoplasms
dc.subjectReceptor, erbB-2
dc.subjectReceptors, Estrogen
dc.subjectReceptors, Progesterone
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDisease-Free Survival
dc.subjectInfusions, Intravenous
dc.subjectSurvival Rate
dc.subjectProportional Hazards Models
dc.subjectRetrospective Studies
dc.subjectAge Factors
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMeningeal Carcinomatosis
dc.subjectYoung Adult
dc.subjectKaplan-Meier Estimate
dc.subjectInfusions, Spinal
dc.subjectTrastuzumab
dc.subjectAntineoplastic Agents, Immunological
dc.titleTreatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
dc.typeJournal Article
dcterms.dateAccepted2017-07-19
rioxxterms.funderThe Institute of Cancer Research
rioxxterms.identifier.projectUnspecified
rioxxterms.versionofrecord10.1016/j.breast.2017.07.015
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2017-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBreast (Edinburgh, Scotland)
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine Therapy Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine Therapy Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.publication-statusPublished
pubs.volume36
pubs.embargo.termsNot known
icr.researchteamEndocrine Therapy Resistance
icr.researchteamMolecular Oncology
icr.researchteamMedicine (RMH Smith Cunningham)
icr.researchteamTreatment of thoracic tumours
dc.contributor.icrauthorKingston, Belinda
dc.contributor.icrauthorTurner, Nicholas


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record